Navigation Links
Stomach bacteria switch off human immune defences to cause disease
Date:9/1/2013

Helicobacter pylori is a bacterium that establishes a life-long stomach infection in humans, which in some cases can lead to duodenal ulcers or stomach cancer. New research, presented at this week's Society for General Microbiology Autumn Conference, gives us a clearer understanding of how these bacteria can manipulate the human immune system to survive in the mucosal lining of the stomach.

Researchers from the University of Nottingham have shown that H. pylori is able to supress the body's normal production of 'human beta defensin 1' (hβD1), an antimicrobial factor present in the stomach lining that helps prevent bacterial infection. By collecting stomach tissue biopsies from 54 patients at the Queens Medical Centre, Nottingham, the team showed that patients infected with H. pylori had ten times less hβD1 than uninfected patients. Those with the lowest amount of hβD1 had the most bacteria present in their stomach lining.

The most damaging strains of H. pylori make a molecular syringe called the cagT4SS, through which bacterial products are injected into cells of the stomach lining. In vitro work using human gastric epithelial cell lines showed that this activates chemical pathways to suppress hβD1 production. These activated pathways are also involved in the stimulation of an inflammatory response, meaning that these H. pylori strains are able to survive and colonise more abundantly, while continuing to cause tissue damage over many decades. Previous research suggests that chronic inflammation of the stomach lining is strongly linked to gastric cancer.

It is estimated that half of the world's population have H. pylori in the mucosal lining of their stomach. For most people the infection is asymptomatic, although 1-2 per cent of those infected will develop gastric cancer. Survival rates for this disease remain low, as diagnosis is often very late, when the cancer is at an advanced stage.

Katie Cook, who is presenting this work says, "To identify people who are likely to suffer from stomach cancer we need to understand how H. pylori interacts with the cells of the stomach lining. Because our research is patient-focused we know that our findings are directly relevant.

"We hope to combine this work with that being carried out by our colleagues in order to develop a diagnostic test to predict the future risk of gastric cancer development."


'/>"/>

Contact: Benjamin Thompson
b.thompson@sgm.ac.uk
44-075-846-89611
Society for General Microbiology
Source:Eurekalert

Related biology news :

1. UT Southwestern researchers identify novel mechanism that helps stomach bug cause illness
2. Discovery offers insight into treating viral stomach flu
3. Rich or poor in gut bacteria brings new vision for obesity treatment
4. Bacterial toxins cause deadly heart disease
5. UC Davis researchers discover molecular target for the bacterial infection brucellosis
6. High-angle helix helps bacteria swim
7. Newly discovered bacterial partnership changes ocean chemistry
8. Bacterial blockade
9. Study finds depletion of alveolar macrophages linked to bacterial super-infections
10. New methods to visualize bacterial cell-to-cell communication
11. Bacteria from Salar de Uyuni in Bolivia conceal bioplastic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... on Friday, February 24, 2017 a total of 10,672,750 common ... $0.13 per common share. Proceeds from the exercise of these ... InMed,s Treasury.   ... "We are grateful for this expression of confidence by ...
(Date:2/27/2017)... NEW YORK , February 27, 2017 ... up by Stock-Callers.com for evaluation today, and they are: ... ARWR), Pacific Biosciences of California Inc. (NASDAQ: PACB), and ... to an article on ETF Trends, market observers are ... Congress and administration could enact reforms to free cash ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences announced ... has been appointed as a Certified Service ... IsoFlux system will be used in Genetracer Biotech,s novel ... lung and colon cancer, with plans to move to ... is utilizing Fluxion,s IsoFlux System to isolate, recover, and ...
(Date:2/27/2017)... ... 27, 2017 , ... The Catalyst Midwest premix manufacturing facility has ... premix services and private label organic services. , The first organic product is Organic ... operating officer of Dynamite Marketing, which owns the facility. , Catalyst already has received ...
Breaking Biology Technology: